With a new Administration in place, many are eager to see what changes are potentially in store for the 340B Drug Pricing Program and other health care initiatives that directly and indirectly affect it and its key stakeholders. While still in the midst of pandemic response efforts and taking into consideration any other legislative, regulatory, and judicial actions expected in 2021, we’ll examine the most pressing issues impacting those directly involved with 340B efforts at their organization.
In this third iteration, the day-long webinar series continues the conversation for and between covered entities and manufacturers with a reflection on potential policies and developments as a result of the new Administration, the continuing dispute between providers and manufacturers around contract pharmacy arrangements, and insight on business practices that will help your organization with its 340B efforts. Participate in one or all of the sessions of the day to gain insight into the current climate and strategies to improve your operations, such as addressing duplicate discounts, getting the most out of your data, and ensuring program integrity and compliance.
Click here for additional information and registration details.
